Brief: Cyclacel Doses First Patient In Phase 1/2 Study Of Oral CYC140

Bio Green Med Solution

19/04/2022 14:19

April 19 (Reuters) - Cyclacel Pharmaceuticals Inc  CYCC.O :
    * CYCLACEL ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1/2
STUDY OF
ORAL CYC140 IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS

Source text for Eikon:  ID:nGNX4bVY4p 
Further company coverage:  CYCC.O 

 ((Reuters.Briefs@thomsonreuters.com;))